Skip to main content
. 2018 Feb;110(2):124–131. doi: 10.5935/abc.20180016

Table 1.

Demographic and clinical characteristics

Variables Subjects (n = 61) Indeterminate
form (n = 17)
Cardiac form without ventricular dysfunction (n = 16) Cardiac form with ventricular dysfunction (n = 28)
Demographic characteristics        
Age (years), mean ± standard deviation 58 ± 8 59 ± 11 59 ± 9 58 ± 7
Female, n (%) 36 (59) 12 (70) 12 (75) 12 (43)
Lived in a mud house, n (%) 50 (82) 15 (88) 15 (94) 20 (71)
Family members with positive serology, n (%) 39 (64) 11 (65) 14 (88) 14 (50)
Digestive form, n (%) 4 (6.6) - 2 (12) 2 (7)
Body mass index (kg/m2), mean ± standard deviation 25 ± 4 26 ± 4 27 ± 4 26 ± 3
Comorbidities, n (%)        
Arterial hypertension 44 (72) 14 (82) 12 (75) 18 (64)
Diabetes mellitus 9 (15) 4 (23) - 5 (18)
Syncope 6 (7) 1 (6) 1 (6) 2 (7)
Smoking 16 (26) 3 (18) 3 (18) 10 (36)
Congestive heart failure NYHA III/IV 16 (26) - - 16 (57)*
Laboratory characteristics        
Creatinine (mg/dL) 0.88 (0.7 - 0.99) 0.84 (0.7 - 0.98) 0.78 (0.6 - 0.91) 0.94 (0.7 - 1.0)
Sodium (mmoL/dL) 140 ± 3 138 ± 2 139 ± 2 139 ± 2
Hemoglobin (g/dL) 13.9 ± 0.9 14.2 ± 1.3 13.4 ± 0.7 14.2 ± 1.0
Total Cholesterol (mg/dL) 193 ± 38 202 ± 40 194 ± 42 200 ± 45
Reactive C protein (mg/dL) 1.15 (0.63 - 4.02) 1.71 (0.35 - 6.54) 1.24 (0.51 - 4.74) 1.09 (0.73 - 3.62)
NT-ProBNP (pg/mL) 686 (66 - 816) 60.5 (34 - 108) 96.0 (73 - 181) 839.5** (189 - 2271)
Troponin I (ng/mL) 0.684 (0.012 - 0.04) 0.012 (0.012 - 0.012) 0.012 (0.012 - 0.028) 0.038 (0.019 - 0.06)
LVEF (%) 54 ± 15 64 ± 3 64 ± 4 43 ± 10*
METS 9 ± 2.5 12 ± 3 9 ± 2 8 ± 2

NYHA: New York Heart Association; NT-ProBNP: N-terminal pro B-type natriuretic peptide; LVEF: left ventricular ejection fraction; METS: metabolic equivalent of task. Data expressed as mean ± standard deviation or percentage (%) for discrete variables and median and interquartile range for continuous variables with non-normal distribution.

*

p < 0.001, Fisher's exact text.

**

p < 0.001, Kruskal-Wallis one-way analysis of variance.